Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$460K
Filings
59
Firms Hired
4
Active Period
2010–2015
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Drug Quality and Security Act
2013 · third_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. Public Law No. 112-144 Food and Drug Administration safety and Innovation Act. HR 3204, Drug Quality and Security Act/S. 959 Pharmaceutical Quality, Security and Accountability Act.
Client expense: — · Firm income: $30,000
Matched citations: HR 3204
Pharmaceutical Quality, Security, and Accountability Act
2013 · third_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. Public Law No. 112-144 Food and Drug Administration safety and Innovation Act. HR 3204, Drug Quality and Security Act/S. 959 Pharmaceutical Quality, Security and Accountability Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 959
Drug Quality and Security Act
2013 · fourth_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. Public Law No: 112-144 Food and Drug Administration Safety and Innovation Act HR 3204 Drug Quality and Security Act/S. 959 Pharmaceutical Quality, Security and Accountability Act.
Client expense: — · Firm income: $30,000
Matched citations: HR 3204
Pharmaceutical Quality, Security, and Accountability Act
2013 · fourth_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. Public Law No: 112-144 Food and Drug Administration Safety and Innovation Act HR 3204 Drug Quality and Security Act/S. 959 Pharmaceutical Quality, Security and Accountability Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 959
Drug Quality and Security Act
2013 · third_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. Public Law No: 112-144 Food and Drug Administration Safety and Innovation Act HR 3204 Drug Quality and Security Act/S. 959 Pharmaceutical Quality, Security and Accountability Act.
Client expense: — · Firm income: $30,000
Matched citations: HR 3204
Pharmaceutical Quality, Security, and Accountability Act
2013 · third_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. Public Law No: 112-144 Food and Drug Administration Safety and Innovation Act HR 3204 Drug Quality and Security Act/S. 959 Pharmaceutical Quality, Security and Accountability Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 959
Safeguarding America's Pharmaceuticals Act of 2013
2013 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
nnovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. Public Law No: 112-144 Food and Drug Administration Safety and Innovation Act HR 1919 Safeguarding America's Pharmaceuticals Act of 2013/S. 957 Drug Supply Chair Security Act
Client expense: — · Firm income: $30,000
Matched citations: HR 1919
Drug Supply Chain Security Act
2013 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
nnovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. Public Law No: 112-144 Food and Drug Administration Safety and Innovation Act HR 1919 Safeguarding America's Pharmaceuticals Act of 2013/S. 957 Drug Supply Chair Security Act
Client expense: — · Firm income: $30,000
Matched citations: S. 957
Preserving Access to Life-Saving Medications Act of 2011
2012 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act
Client expense: — · Firm income: $30,000
Matched citations: HR 2245
Preserving Access to Life-Saving Medications Act of 2011
2012 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act
Client expense: — · Firm income: $30,000
Matched citations: HR 2245
FAST Act
2012 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act
Client expense: — · Firm income: $30,000
Matched citations: HR 4132
FAST Act
2012 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act
Client expense: — · Firm income: $30,000
Matched citations: HR 4132
Preserving Access to Life-Saving Medications Act of 2011
2012 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization
Client expense: — · Firm income: $30,000
Matched citations: HR 2245
Preserving Access to Life-Saving Medications Act of 2011
2012 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization
Client expense: — · Firm income: $30,000
Matched citations: HR 2245
FAST Act
2012 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization
Client expense: — · Firm income: $30,000
Matched citations: HR 4132
FAST Act
2012 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization
Client expense: — · Firm income: $30,000
Matched citations: HR 4132
Preserving Access to Life-Saving Medications Act of 2011
2012 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act
Client expense: — · Firm income: $30,000
Matched citations: HR 2245
Preserving Access to Life-Saving Medications Act of 2011
2012 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act
Client expense: — · Firm income: $30,000
Matched citations: HR 2245
FAST Act
2012 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act
Client expense: — · Firm income: $30,000
Matched citations: HR 4132
FAST Act
2012 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act
Client expense: — · Firm income: $30,000
Matched citations: HR 4132
Preserving Access to Life-Saving Medications Act of 2011
2012 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization
Client expense: — · Firm income: $30,000
Matched citations: HR 2245
Preserving Access to Life-Saving Medications Act of 2011
2012 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization
Client expense: — · Firm income: $30,000
Matched citations: HR 2245
FAST Act
2012 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization
Client expense: — · Firm income: $30,000
Matched citations: HR 4132
FAST Act
2012 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization
Client expense: — · Firm income: $30,000
Matched citations: HR 4132
Source: Senate LDA